Plus Therapeutics’ (PSTV) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Plus Therapeutics (NASDAQ:PSTV) in a research note released on Tuesday morning,Benzinga reports. They currently have a $8.00 target price on the stock.

Separately, Ascendiant Capital Markets reduced their price target on shares of Plus Therapeutics from $21.00 to $20.00 and set a “buy” rating on the stock in a research report on Tuesday, September 3rd.

Plus Therapeutics Trading Down 1.6 %

Shares of Plus Therapeutics stock opened at $1.26 on Tuesday. The business’s 50-day moving average price is $1.36 and its 200-day moving average price is $1.62. The firm has a market capitalization of $7.43 million, a PE ratio of -0.50 and a beta of 0.69. Plus Therapeutics has a 12 month low of $1.12 and a 12 month high of $2.67.

Institutional Investors Weigh In On Plus Therapeutics

A hedge fund recently bought a new stake in Plus Therapeutics stock. AIGH Capital Management LLC purchased a new position in Plus Therapeutics, Inc. (NASDAQ:PSTV) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 568,681 shares of the company’s stock, valued at approximately $836,000. AIGH Capital Management LLC owned 9.98% of Plus Therapeutics at the end of the most recent reporting period. 3.28% of the stock is currently owned by institutional investors.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.